Abstract: The present technology provides methods for treating pancreatic cancer using a MEK inhibitor and a CDK4/6 inhibitor. Also disclosed herein are methods for increasing patient responsiveness to chemotherapeutic and/or immunotherapeutic regimes for pancreatic cancer. Kits for use in practicing the methods are also provided.

Abstract: An adjustable seal includes a first ring extending about an axis and including a plurality of first teeth. The adjustable seal also includes a second ring extending about the axis and including a plurality of second teeth. The first ring and the second ring cooperatively defining a passage extending along the axis. The adjustable seal has a locked configuration in which the second teeth engage the first teeth and prevent movement of the first ring relative to the second ring, and an unlocked configuration in which the first ring is able to rotate relative to the second ring. The adjustable seal also includes a flexible member attached to the first ring and the second ring. Rotation of the first ring relative to the second ring in the unlocked configuration of the adjustable seal causes the flexible member to extend across at least a portion of the passage defined by the first ring and the second ring.

Abstract: Provided herein are compounds and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of conditions associated with inhibition of HDAC (e.g,. HDAC2).

Abstract: This invention provides compounds that are inhibitors of HDAC2. The compounds (e.g., compounds according to Formula I, II or any of Compounds 100-128 or any of those in Tables 2 or 3) accordingly are useful for treating, alleviating, or preventing a condition in a subject such as a neurological disorder, memory or cognitive function disorder or impairment, extinction learning disorder, fungal disease or infection, inflammatory disease, hematological disease, or neoplastic disease, or for improving memory or treating, alleviating, or preventing memory loss or impairment.

Abstract: Purified recombinant polypeptides isolated from Chinese hamster ovary host cells, including antibodies, such as therapeutic antibodies, and methods of making and using such polypeptides are provided.

Abstract: Provided herein are compounds and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of conditions associated with inhibition of HDAC (e.g., HDAC2).

Abstract: Provided herein are compounds and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of conditions associated with inhibition of HDAC (e.g,. HDAC2).

Abstract: A valve for m exhaust gas recirculation Mae in an engine includes a first barrel connectable to a first group of cylinders, a second barrel connectable to a second group of cylinders, and a center barrel between the first and second barrels and connectable to an intake of the engine, A poppet valve with two valve heads mounted on a valve stem is provided to open and close openings between the first and second barrels, with one of the valve beads of the poppet valve opening into the center barrel Vanes are provided in the center barrel to direct flow from the opening by the valve bead that opens into the center barrel toward the outlet opening.

Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.

Abstract: Many attempts at translating real-time events (e.g., sporting events) to augmented reality (AR)-based, extended or Data Processing Service and Technology Environment cross reality (XR)-based, or virtual reality (VR)-based experiences and environments rely upon mapping captured surface image data (such as video, pictures, etc.) of objects (e.g., balls, players, etc.) onto computer-modeled environments. This surface mapping results in imperfect and unsatisfactory virtual reality experiences for the viewer because the images and sounds do not perfectly correlate to the motion and states of the real-time objects and players. To solve this problem, and create an improved experience fo the virtual spectator, a more accurate and immersive virtual, extended, or aumented reality environment can be created by relying on data from a network system of sensors embedded throughout the real-time environment during the event in question.

Abstract: Provided herein are compounds and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of conditions associated with inhibition of HDAC (e.g,. HDAC2).

Abstract: The present invention relates to compounds of Formula I:

Abstract: Provided herein are compounds and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of conditions associated with inhibition of HDAC (e.g., HDAC2).

Abstract: Provided herein are compounds and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of conditions associated with inhibition of HDAC (e.g., HDAC2).

Abstract: This invention provides compounds that are inhibitors of HDAC2. The compounds (e.g., compounds according to Formula I, II or any of Compounds 100-128 or any of those in Tables 2 or 3) accordingly are useful for treating, alleviating, or preventing a condition in a subject such as a neurological disorder, memory or cognitive function disorder or impairment, extinction learning disorder, fungal disease or infection, inflammatory disease, hematological disease, or neoplastic disease, or for improving memory or treating, alleviating, or preventing memory loss or impairment.

Abstract: Provided herein are compounds of Formula I and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with histone deacetylases (HDAC).

Abstract: Provided herein are compounds of the Formula (I): and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with histone deacetylases (HDAC).

Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.

Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.

Abstract: Provided herein are compounds and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of conditions associated with inhibition of HDAC (e.g. HDAC2).